Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00500721|
Recruitment Status : Completed
First Posted : July 13, 2007
Last Update Posted : April 14, 2008
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: HCV-796 Drug: Desipramine||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||August 2007|
|Actual Study Completion Date :||August 2007|
- Drug: HCV-796
HCV-796 500mg BID x 14 days
- Drug: Desipramine
Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.
Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.
Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10.
- Pharmacokinetic (PK) [ Time Frame: 21 days ]
- Safety [ Time Frame: 29 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00500721
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19148|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|